

## Press Release

### **Transfer of Sale and Distribution, and Termination of Co-promotion for Symbicort<sup>®</sup> Turbuhaler<sup>®</sup>**

**TOKYO and OSAKA January 17, 2018** - Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., “Astellas” ) and AstraZeneca K.K. (Representative Director and President: Stefan Woxström) today announced that the sale and distribution of Symbicort<sup>®</sup> Turbuhaler<sup>®</sup> 30 doses and Symbicort<sup>®</sup> Turbuhaler<sup>®</sup> 60 doses (“the product”), the inhalation dry-powder treatment for asthma and chronic obstructive pulmonary disease (“COPD”), conducted by Astellas in Japan will be transferred to AstraZeneca K.K., and that the co-promotion conducted by Astellas and AstraZeneca K.K. will be terminated on July 30, 2019. AstraZeneca K.K. will solely distribute and promote the product in Japan from July 31, 2019.

The termination of the sale and distribution by Astellas and the co-promotion by both companies of the product is due to the expiration of the sale and co-promotion agreement concluded in 2009 by Astellas and AstraZeneca AB (Headquarter; Sweden), an affiliated company of AstraZeneca K.K.

The product, a twice daily inhalation dry-powder treatment for asthma and COPD, combines an inhaled corticosteroid budesonide and a rapid and long-acting  $\beta_2$  agonist formoterol fumarate dihydrate within a single dry powder inhalation device. The product was launched in Japan in January 2010. AstraZeneca K.K. has manufactured and developed, and Astellas has distributed, and both companies have jointly promoted the product.

#### **List of the products**

Symbicort<sup>®</sup> Turbuhaler<sup>®</sup> 30 doses

Symbicort<sup>®</sup> Turbuhaler<sup>®</sup> 60 doses

**About Astellas**

Astellas Pharma Inc., based in Tokyo, Japan, is a company dedicated to improving the health of people around the world through the provision of innovative and reliable pharmaceutical products. For more information, please visit our website at <https://www.astellas.com/en>

**About AstraZeneca K.K.**

AstraZeneca is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three therapy areas - Oncology, Cardiovascular, Renal & Metabolism and Respiratory. AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. For more information, please visit [www.astrazeneca.com](http://www.astrazeneca.com) and follow us on Twitter @AstraZeneca.

###

---

**Contacts for inquiries or additional information:**

Astellas Pharma Inc.

Corporate Communications

TEL: +81-3-3244-3201 FAX: +81-3-5201-7473

AstraZeneca K.K.

Corporate Affairs, Ikei

TEL: +81-3-6268-2800 / +81-70-1369-2228